Drug class in one race
PARP drugs for HR+/HER2- Metastatic Breast Cancer
2 tracked PARP drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the PARP page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
2 approved / phase 4
Head-to-head evidence: Olaparib vs Talazoparib